Brief: BioCryst Pharmaceuticals Q2 EPS USD -0.06 Vs. IBES Estimate USD -0.17
05/08/2024 12:01
Aug 05 (Reuters) - BioCryst Pharmaceuticals Q2 pretax profit USD -12.502 million vs. IBES estimate USD -32.7 million. * Q2 operating expenses USD 100.571 million * Q2 operating income USD 8.761 million vs. IBES estimate USD -10.3 million * Q2 net income USD -12.674 million vs. IBES estimate USD -35.9 million * Q2 product sales USD 109.332 million
Recent news on BioCryst Pharmaceuticals
See all newsUS RESEARCH ROUNDUP-Alnylam Pharmaceuticals, Carvana, MongoDB
Pharvaris' genetic disorder drug meets main goal in late-stage trial (updated)
Brief: Biocryst Announces Approval Of Orladeyo® For Pediatric Hae Patients In Japan
BioCryst Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Brief: Biocryst Pharmaceuticals, - Cash, Cash Equivalents, Restricted Cash And Investments $354 Million At June 30, 2026